About US
Contact us
>>Back
Sanofi to continue developing Prednisporin under sub-licencing agreement
- Publisher：
- Publication：2012/10/31
Sanofi has announced in its latest quarterly financial update that the company intends to continue developing Prednisporin under the terms of a sublicense agreement with a third party.
Prednisporin is a fixed combination of prednispolone acetate and cyclosporine A, which is used in the treatment of several ophthalmologic conditions, including persistent allergic conjunctivitis.
The drug was licenced by Zalicus in 2006 to Focea Pharmaceuticals, which is now a division of Sanofi.
Following a review of results from Phase 2b trials, the company said that it has reassessed the commercial profile of Prednisporin with a view to its continued development.
"We are pleased that Prednisporin remains in the Sanofi clinical development pipeline and anticipate that the proposed sublicense by Sanofi will allow for the continued clinical development andpotential commercialisation of Prednisporin," said Mark Corrigan MD, president of Zalicus.
Under the terms of Zalicus' second amended and restated research and licence agreement with Sanofi, the later is permitted to sub-licence its rights to develop and commercialise the drug on a global basis.
However, the royalties due to Zalicus continue to apply in such a scenario.